the traditional analgesic mode

PreclinicalSmall molecule

TThe Affiliated Hospital of Putian University

the traditional analgesic mode is one of 40 small molecule programs targeting Abscess. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AbscessActive, not recruiting

AbscessPreclinical

Active, not recruiting

Competition

Competitive Landscape

64 competitors in Abscess

#DrugCompanyPhaseTrials

Valtrex

GGlaxo Dba Glaxosmithkline

Approved

2 2

Flagyl

DDePuy Orthopaedics

Approved

1 3

Duragesic

CCephalon

Approved

1 4

Activase

Roche

Phase 3

1 5

Mycobutin

Pfizer

Phase 3

1 6

Biaxin

AbbVie

Phase 3

1 7

Primaxin

Pfizer

Phase 3

1 8

Sirturo

WWim Janssens

Phase 3

2 9

MS Contin

HHikma Pharmaceuticals LLC

Phase 3

1 10

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Abscess

NCT07358065

Clinical

Trials by Indication[1]

Abscess1 trial

Clinical Application of Dynamic Multimodal Analgesia Regimen After Perianal Abscess Surgery

Not yet recruiting·TThe Affiliated Hospital of Putian University·N/A·NCT07358065·135 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for the traditional analgesic mode. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — the traditional analgesic mode compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for the traditional analgesic mode. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Affiliated Hospital of Putian University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe Affiliated Hospital of Putian University

the traditional analgesic mode

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Abscess1 trial

References

Drug Info

Quick Facts

Related News